US HB3379 | 2019-2020 | 116th Congress

Status

Spectrum: Partisan Bill (Democrat 22-1)
Status: Introduced on June 20 2019 - 25% progression, died in committee
Action: 2019-06-21 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period. This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

PRICED Act Price Relief, Innovation, and Competition for Essential Drugs Act

Sponsors


History

DateChamberAction
2019-06-21HouseReferred to the Subcommittee on Health.
2019-06-20HouseReferred to the House Committee on Energy and Commerce.
2019-06-20HouseIntroduced in House

Same As/Similar To

SB4796 (Related) 2020-10-05 - Read twice and referred to the Committee on Finance.
HB8527 (Related) 2020-10-02 - Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Subjects


US Congress State Sources


Bill Comments

feedback